BELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC) (BELIEF)

Clinical Trial ID NCT01562028

Rank	Title	Journal	Year	PubWeight™‹?›
1	EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.	Science	2004	61.56
2	EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.	N Engl J Med	2005	26.35
3	Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.	Lancet Oncol	2012	22.04
4	Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC).	Transl Lung Cancer Res	2015	0.94
5	Non-Small Cell Lung Cancer beyond Biomarkers: The Evolving Landscape of Clinical Trial Design.	J Pers Med	2014	0.92
6	Novel small molecule EGFR inhibitors as candidate drugs in non-small cell lung cancer.	Onco Targets Ther	2013	0.85
7	The role of anti-angiogenesis in non-small-cell lung cancer: an update.	Curr Oncol Rep	2015	0.79
8	Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC.	Front Oncol	2016	0.79